SuperworthOS Therapies OSTX
- Market cap
- $57.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
OS Therapies' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $454.5K | $1M | $361.8K−52% | $396.6K−60% | $1.2M+166% | $870.5K−15% | $1.3M+262% | $2.5M+530% | $3.8M+210% | $8.8M+911% | $7.4M+462% | $6.1M+143% |
| SG&A | $167.7K | $138K | $268.4K−9% | $383.2K−27% | $1.2M+632% | $2.1M+1418% | $3.7M+1275% | $2.3M+510% | $3.1M+155% | $3.2M+52% | $2.8M−24% | $2.5M+7% |
| −$622.2K | −$1.2M | −$630.2K−40% | −$779.8K−49% | −$2.4M+292% | −$3M+156% | −$5M+693% | −$4.8M+521% | −$6.9M+182% | −$12M+304% | −$10.2M+103% | −$8.6M+77% | |
| Interest expense | $1.4M | $307.5K | $828.8K+4% | $777.7K−21% | $437.8K−68% | $7.6K−98% | n/a | n/a | n/a | n/a | $75.3K | $5.6K |
| Net income | −$2M | −$1.5M | −$1.5M−21% | −$1.6M−38% | −$2.9M+46% | −$3M+104% | −$3.9M+166% | −$4.5M+191% | −$6.9M+139% | −$13.5M+350% | −$10.4M+168% | −$8.6M+90% |
| −$0.38 | n/a | −$0.25−29% | −$0.26−45% | −$0.18−53% | −$0.23 | −$0.18−28% | −$0.19−27% | −$0.21+17% | −$1.23+435% | −$0.27+50% | −$0.20+5% | |
| 5.3M | n/a | 6M+12% | 6M+12% | 15.9M+198% | 21.7M | 21.2M+255% | 25.1M+319% | 32M+101% | 11M−49% | 38.7M+82% | 43.9M+75% |
EPS, diluted: 5 periods, Q1 FY23 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY23: share-days: the 6-month average less the second quarter's. Q4 FY24: not printed by the filing, worked out from its own lines. Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x1.781).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest OS Therapies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| OSTXOS Therapies | $57.7M | n/m | n/a | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| Peer median | $213.8M | 12.0× | 14.9× | 1.4× | −3% | 7.6% |
More on OS Therapies
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .